Salix Pharmaceuticals Ltd. (SLXP) Stock Reaches A New High

18

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) has recently reported late-stage results for rifaximin, also known as Xifaxan. The drug was developed as a repeat treatment for patients with irritable bowel syndrome with diarrhea. The company is primarily focused on developing treatment for gastrointestinal diseases.

The company announced study results Tuesday morning that a statistically significant greater proportion of subjects treated with rifaximin responded positively to repeat treatment in the TARGET 3 Phase 3 study.

The stock opened on Tuesday at $138.30, and set a new high for the year.

The company is also awaiting the Food and Drug Administration’s decision on ruconest, a hereditary angioedema drug. Salix acquired the drug when it purchased Santarus for $2.6 billion. Experts say there is a 50-50 chance that it will be approved.

Get Free Updates and Stock Alerts!



*We only send one email per week
Share.

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join UltimateStockAlerts.com now before you miss out on our next big runner!

We will never sell or share your information.